Chemical & Material
Global Nutritional Supplements in Psychiatric Disorders Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 18, 25
- ID: 603074
- Pages: 133
- Figures: 136
- Views: 1
Report Includes:
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Nutritional Supplements in Psychiatric Disorders market, seamlessly integrating production capacity and sales performance across the value chain. It analyzes historical production, revenue, and sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—capacity, sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Now Foods
Nature’s Bounty
Garden of Life
Nordic Naturals
Jarrow Formulas
Thorne Research
Pure Encapsulations
Integrative Therapeutics
Life Extension
Metagenics
Segment by Type
Omega-3 Fatty Acids
Amino Acids
Vitamins
Herbal Supplements
Others
Segment by Application
Clinical Practice
Research and Development
Personalized Medicine
Other
Production by Region
North America
Europe
China
Japan
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Nutritional Supplements in Psychiatric Disorders study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Maps global production capacity, utilization, and market share (2020–2031), identifies efficient hubs, reveals regulatory/trade policy impacts and bottlenecks.
Chapter 4: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 5: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 6: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 7: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 8: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 9: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 10: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 11: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 12: Profiles manufacturers in depth—details product specs, capacity, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 13: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint and technology, cost drivers, plus downstream channels and distributor roles.
Chapter 14: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 7–11) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 13) and customers (Chapter 6) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 4 and 12).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 13 and 14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Nutritional Supplements in Psychiatric Disorders market, seamlessly integrating production capacity and sales performance across the value chain. It analyzes historical production, revenue, and sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—capacity, sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Now Foods
Nature’s Bounty
Garden of Life
Nordic Naturals
Jarrow Formulas
Thorne Research
Pure Encapsulations
Integrative Therapeutics
Life Extension
Metagenics
Segment by Type
Omega-3 Fatty Acids
Amino Acids
Vitamins
Herbal Supplements
Others
Segment by Application
Clinical Practice
Research and Development
Personalized Medicine
Other
Production by Region
North America
Europe
China
Japan
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Nutritional Supplements in Psychiatric Disorders study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Maps global production capacity, utilization, and market share (2020–2031), identifies efficient hubs, reveals regulatory/trade policy impacts and bottlenecks.
Chapter 4: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 5: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 6: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 7: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 8: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 9: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 10: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 11: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 12: Profiles manufacturers in depth—details product specs, capacity, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 13: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint and technology, cost drivers, plus downstream channels and distributor roles.
Chapter 14: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 7–11) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 13) and customers (Chapter 6) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 4 and 12).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 13 and 14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Nutritional Supplements in Psychiatric Disorders: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Nutritional Supplements in Psychiatric Disorders Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Omega-3 Fatty Acids
1.2.3 Amino Acids
1.2.4 Vitamins
1.2.5 Herbal Supplements
1.2.6 Others
1.3 Market Segmentation by Application
1.3.1 Global Nutritional Supplements in Psychiatric Disorders Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Clinical Practice
1.3.3 Research and Development
1.3.4 Personalized Medicine
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Nutritional Supplements in Psychiatric Disorders Revenue Estimates and Forecasts 2020-2031
2.2 Global Nutritional Supplements in Psychiatric Disorders Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Nutritional Supplements in Psychiatric Disorders Sales Estimates and Forecasts 2020-2031
2.4 Global Nutritional Supplements in Psychiatric Disorders Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Global Production Analysis
3.1 Global Nutritional Supplements in Psychiatric Disorders Production Capacity and Utilization Rates (2020–2031)
3.2 Regional Production: Comparative Analysis (2020 VS 2024 VS 2031)
3.3 Regional Production Dynamics
3.3.1 Historic Production by Region (2020-2025)
3.3.2 Forecasted Production by Region (2026-2031)
3.3.3 Production Market Share by Region (2020-2031)
3.3.4 Regulatory and Trade Policy Impact on Production
3.3.5 Production Capacity Enablers and Constraints
3.4 Key Regional Production Hubs
3.4.1 North America
3.4.2 Europe
3.4.3 China
3.4.4 Japan
4 Competition by Manufacturers
4.1 Global Nutritional Supplements in Psychiatric Disorders Sales by Manufacturers
4.1.1 Global Sales Volume by Manufacturers (2020-2025)
4.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
4.2 Global Nutritional Supplements in Psychiatric Disorders Manufacturer Revenue Rankings and Tiers
4.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
4.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
4.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
4.3 Manufacturer Profitability Profiles and Pricing Strategies
4.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
4.3.2 Manufacturer-Level Price Trends (2020-2025)
4.4 Key Manufacturers Manufacturing Base and Headquarters
4.5 Main Product Type Market Size by Manufacturers
4.5.1 Omega-3 Fatty Acids Market Size by Manufacturers
4.5.2 Amino Acids Market Size by Manufacturers
4.5.3 Vitamins Market Size by Manufacturers
4.5.4 Herbal Supplements Market Size by Manufacturers
4.5.5 Others Market Size by Manufacturers
4.6 Global Nutritional Supplements in Psychiatric Disorders Market Concentration and Dynamics
4.6.1 Global Market Concentration (CR5 and HHI)
4.6.2 Entrant/Exit Impact Analysis
4.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
5 Global Product Segmentation Analysis
5.1 Global Nutritional Supplements in Psychiatric Disorders Sales Performance by Type
5.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
5.1.2 Global Sales Market Share by Type (2020-2031)
5.2 Global Nutritional Supplements in Psychiatric Disorders Revenue Trends by Type
5.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
5.2.2 Global Revenue Market Share by Type (2020-2031)
5.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
5.4 Product Technology Differentiation
5.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
5.5.1 High-Growth Niches and Adoption Drivers
5.5.2 Profitability Hotspots and Cost Drivers
5.5.3 Substitution Threats
6 Global Downstream Application Analysis
6.1 Global Nutritional Supplements in Psychiatric Disorders Sales by Application
6.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
6.1.2 Global Sales Market Share by Application (2020-2031)
6.1.3 High-Growth Application Identification
6.1.4 Emerging Application Case Studies
6.2 Global Nutritional Supplements in Psychiatric Disorders Revenue by Application
6.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
6.2.2 Revenue Market Share by Application (2020-2031)
6.3 Global Pricing Dynamics by Application (2020-2031)
6.4 Downstream Customer Analysis
6.4.1 Top Customers by Region
6.4.2 Top Customers by Application
7 North America
7.1 North America Sales Volume and Revenue (2020-2031)
7.2 North America Key Manufacturers Sales Revenue in 2024
7.3 North America Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Type (2020-2031)
7.4 North America Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Application (2020-2031)
7.5 North America Growth Accelerators and Market Barriers
7.6 North America Nutritional Supplements in Psychiatric Disorders Market Size by Country
7.6.1 North America Revenue by Country
7.6.2 North America Sales Trends by Country
7.6.3 US
7.6.4 Canada
7.6.5 Mexico
8 Europe
8.1 Europe Sales Volume and Revenue (2020-2031)
8.2 Europe Key Manufacturers Sales Revenue in 2024
8.3 Europe Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Type (2020-2031)
8.4 Europe Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Application (2020-2031)
8.5 Europe Growth Accelerators and Market Barriers
8.6 Europe Nutritional Supplements in Psychiatric Disorders Market Size by Country
8.6.1 Europe Revenue by Country
8.6.2 Europe Sales Trends by Country
8.6.3 Germany
8.6.4 France
8.6.5 U.K.
8.6.6 Italy
8.6.7 Russia
9 Asia-Pacific
9.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
9.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
9.3 Asia-Pacific Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Type (2020-2031)
9.4 Asia-Pacific Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Application (2020-2031)
9.5 Asia-Pacific Nutritional Supplements in Psychiatric Disorders Market Size by Region
9.5.1 Asia-Pacific Revenue by Region
9.5.2 Asia-Pacific Sales Trends by Region
9.6 Asia-Pacific Growth Accelerators and Market Barriers
9.7 Southeast Asia
9.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
9.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand
9.8 China
9.9 Japan
9.10 South Korea
9.11 China Taiwan
9.12 India
10 Central and South America
10.1 Central and South America Sales Volume and Revenue (2020-2031)
10.2 Central and South America Key Manufacturers Sales Revenue in 2024
10.3 Central and South America Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Type (2020-2031)
10.4 Central and South America Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Application (2020-2031)
10.5 Central and South America Investment Opportunities and Key Challenges
10.6 Central and South America Nutritional Supplements in Psychiatric Disorders Market Size by Country
10.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 Brazil
10.6.3 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
11.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
11.3 Middle East and Africa Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Type (2020-2031)
11.4 Middle East and Africa Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Application (2020-2031)
11.5 Middle East and Africa Investment Opportunities and Key Challenges
11.6 Middle East and Africa Nutritional Supplements in Psychiatric Disorders Market Size by Country
11.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
11.6.2 GCC Countries
11.6.3 Turkey
11.6.4 Egypt
11.6.5 South Africa
12 Corporate Profile
12.1 Now Foods
12.1.1 Now Foods Corporation Information
12.1.2 Now Foods Business Overview
12.1.3 Now Foods Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.1.4 Now Foods Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.1.5 Now Foods Nutritional Supplements in Psychiatric Disorders Sales by Product in 2024
12.1.6 Now Foods Nutritional Supplements in Psychiatric Disorders Sales by Application in 2024
12.1.7 Now Foods Nutritional Supplements in Psychiatric Disorders Sales by Geographic Area in 2024
12.1.8 Now Foods Nutritional Supplements in Psychiatric Disorders SWOT Analysis
12.1.9 Now Foods Recent Developments
12.2 Nature’s Bounty
12.2.1 Nature’s Bounty Corporation Information
12.2.2 Nature’s Bounty Business Overview
12.2.3 Nature’s Bounty Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.2.4 Nature’s Bounty Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.2.5 Nature’s Bounty Nutritional Supplements in Psychiatric Disorders Sales by Product in 2024
12.2.6 Nature’s Bounty Nutritional Supplements in Psychiatric Disorders Sales by Application in 2024
12.2.7 Nature’s Bounty Nutritional Supplements in Psychiatric Disorders Sales by Geographic Area in 2024
12.2.8 Nature’s Bounty Nutritional Supplements in Psychiatric Disorders SWOT Analysis
12.2.9 Nature’s Bounty Recent Developments
12.3 Garden of Life
12.3.1 Garden of Life Corporation Information
12.3.2 Garden of Life Business Overview
12.3.3 Garden of Life Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.3.4 Garden of Life Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.3.5 Garden of Life Nutritional Supplements in Psychiatric Disorders Sales by Product in 2024
12.3.6 Garden of Life Nutritional Supplements in Psychiatric Disorders Sales by Application in 2024
12.3.7 Garden of Life Nutritional Supplements in Psychiatric Disorders Sales by Geographic Area in 2024
12.3.8 Garden of Life Nutritional Supplements in Psychiatric Disorders SWOT Analysis
12.3.9 Garden of Life Recent Developments
12.4 Nordic Naturals
12.4.1 Nordic Naturals Corporation Information
12.4.2 Nordic Naturals Business Overview
12.4.3 Nordic Naturals Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.4.4 Nordic Naturals Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.4.5 Nordic Naturals Nutritional Supplements in Psychiatric Disorders Sales by Product in 2024
12.4.6 Nordic Naturals Nutritional Supplements in Psychiatric Disorders Sales by Application in 2024
12.4.7 Nordic Naturals Nutritional Supplements in Psychiatric Disorders Sales by Geographic Area in 2024
12.4.8 Nordic Naturals Nutritional Supplements in Psychiatric Disorders SWOT Analysis
12.4.9 Nordic Naturals Recent Developments
12.5 Jarrow Formulas
12.5.1 Jarrow Formulas Corporation Information
12.5.2 Jarrow Formulas Business Overview
12.5.3 Jarrow Formulas Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.5.4 Jarrow Formulas Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.5.5 Jarrow Formulas Nutritional Supplements in Psychiatric Disorders Sales by Product in 2024
12.5.6 Jarrow Formulas Nutritional Supplements in Psychiatric Disorders Sales by Application in 2024
12.5.7 Jarrow Formulas Nutritional Supplements in Psychiatric Disorders Sales by Geographic Area in 2024
12.5.8 Jarrow Formulas Nutritional Supplements in Psychiatric Disorders SWOT Analysis
12.5.9 Jarrow Formulas Recent Developments
12.6 Thorne Research
12.6.1 Thorne Research Corporation Information
12.6.2 Thorne Research Business Overview
12.6.3 Thorne Research Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.6.4 Thorne Research Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.6.5 Thorne Research Recent Developments
12.7 Pure Encapsulations
12.7.1 Pure Encapsulations Corporation Information
12.7.2 Pure Encapsulations Business Overview
12.7.3 Pure Encapsulations Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.7.4 Pure Encapsulations Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.7.5 Pure Encapsulations Recent Developments
12.8 Integrative Therapeutics
12.8.1 Integrative Therapeutics Corporation Information
12.8.2 Integrative Therapeutics Business Overview
12.8.3 Integrative Therapeutics Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.8.4 Integrative Therapeutics Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.8.5 Integrative Therapeutics Recent Developments
12.9 Life Extension
12.9.1 Life Extension Corporation Information
12.9.2 Life Extension Business Overview
12.9.3 Life Extension Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.9.4 Life Extension Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.9.5 Life Extension Recent Developments
12.10 Metagenics
12.10.1 Metagenics Corporation Information
12.10.2 Metagenics Business Overview
12.10.3 Metagenics Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.10.4 Metagenics Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.10.5 Metagenics Recent Developments
13 Value Chain and Supply-Chain Analysis
13.1 Nutritional Supplements in Psychiatric Disorders Industry Chain
13.2 Nutritional Supplements in Psychiatric Disorders Upstream Materials Analysis
13.2.1 Raw Materials
13.2.2 Key Suppliers Market Share & Risk Assessment
13.3 Nutritional Supplements in Psychiatric Disorders Integrated Production Analysis
13.3.1 Manufacturing Footprint Analysis
13.3.2 Production Technology Overview
13.3.3 Regional Cost Drivers
13.4 Nutritional Supplements in Psychiatric Disorders Sales Channels and Distribution Networks
13.4.1 Sales Channels
13.4.2 Distributors
14 Nutritional Supplements in Psychiatric Disorders Market Dynamics
14.1 Industry Trends and Evolution
14.2 Market Growth Drivers and Emerging Opportunities
14.3 Market Challenges, Risks, and Restraints
15 Key Findings in the Global Nutritional Supplements in Psychiatric Disorders Study
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.1.1 Research Programs/Design
16.1.1.2 Market Size Estimation
16.1.1.3 Market Breakdown and Data Triangulation
16.1.2 Data Source
16.1.2.1 Secondary Sources
16.1.2.2 Primary Sources
16.2 Author Details
1.1 Introduction to Nutritional Supplements in Psychiatric Disorders: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Nutritional Supplements in Psychiatric Disorders Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Omega-3 Fatty Acids
1.2.3 Amino Acids
1.2.4 Vitamins
1.2.5 Herbal Supplements
1.2.6 Others
1.3 Market Segmentation by Application
1.3.1 Global Nutritional Supplements in Psychiatric Disorders Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Clinical Practice
1.3.3 Research and Development
1.3.4 Personalized Medicine
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Nutritional Supplements in Psychiatric Disorders Revenue Estimates and Forecasts 2020-2031
2.2 Global Nutritional Supplements in Psychiatric Disorders Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Nutritional Supplements in Psychiatric Disorders Sales Estimates and Forecasts 2020-2031
2.4 Global Nutritional Supplements in Psychiatric Disorders Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Global Production Analysis
3.1 Global Nutritional Supplements in Psychiatric Disorders Production Capacity and Utilization Rates (2020–2031)
3.2 Regional Production: Comparative Analysis (2020 VS 2024 VS 2031)
3.3 Regional Production Dynamics
3.3.1 Historic Production by Region (2020-2025)
3.3.2 Forecasted Production by Region (2026-2031)
3.3.3 Production Market Share by Region (2020-2031)
3.3.4 Regulatory and Trade Policy Impact on Production
3.3.5 Production Capacity Enablers and Constraints
3.4 Key Regional Production Hubs
3.4.1 North America
3.4.2 Europe
3.4.3 China
3.4.4 Japan
4 Competition by Manufacturers
4.1 Global Nutritional Supplements in Psychiatric Disorders Sales by Manufacturers
4.1.1 Global Sales Volume by Manufacturers (2020-2025)
4.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
4.2 Global Nutritional Supplements in Psychiatric Disorders Manufacturer Revenue Rankings and Tiers
4.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
4.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
4.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
4.3 Manufacturer Profitability Profiles and Pricing Strategies
4.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
4.3.2 Manufacturer-Level Price Trends (2020-2025)
4.4 Key Manufacturers Manufacturing Base and Headquarters
4.5 Main Product Type Market Size by Manufacturers
4.5.1 Omega-3 Fatty Acids Market Size by Manufacturers
4.5.2 Amino Acids Market Size by Manufacturers
4.5.3 Vitamins Market Size by Manufacturers
4.5.4 Herbal Supplements Market Size by Manufacturers
4.5.5 Others Market Size by Manufacturers
4.6 Global Nutritional Supplements in Psychiatric Disorders Market Concentration and Dynamics
4.6.1 Global Market Concentration (CR5 and HHI)
4.6.2 Entrant/Exit Impact Analysis
4.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
5 Global Product Segmentation Analysis
5.1 Global Nutritional Supplements in Psychiatric Disorders Sales Performance by Type
5.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
5.1.2 Global Sales Market Share by Type (2020-2031)
5.2 Global Nutritional Supplements in Psychiatric Disorders Revenue Trends by Type
5.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
5.2.2 Global Revenue Market Share by Type (2020-2031)
5.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
5.4 Product Technology Differentiation
5.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
5.5.1 High-Growth Niches and Adoption Drivers
5.5.2 Profitability Hotspots and Cost Drivers
5.5.3 Substitution Threats
6 Global Downstream Application Analysis
6.1 Global Nutritional Supplements in Psychiatric Disorders Sales by Application
6.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
6.1.2 Global Sales Market Share by Application (2020-2031)
6.1.3 High-Growth Application Identification
6.1.4 Emerging Application Case Studies
6.2 Global Nutritional Supplements in Psychiatric Disorders Revenue by Application
6.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
6.2.2 Revenue Market Share by Application (2020-2031)
6.3 Global Pricing Dynamics by Application (2020-2031)
6.4 Downstream Customer Analysis
6.4.1 Top Customers by Region
6.4.2 Top Customers by Application
7 North America
7.1 North America Sales Volume and Revenue (2020-2031)
7.2 North America Key Manufacturers Sales Revenue in 2024
7.3 North America Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Type (2020-2031)
7.4 North America Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Application (2020-2031)
7.5 North America Growth Accelerators and Market Barriers
7.6 North America Nutritional Supplements in Psychiatric Disorders Market Size by Country
7.6.1 North America Revenue by Country
7.6.2 North America Sales Trends by Country
7.6.3 US
7.6.4 Canada
7.6.5 Mexico
8 Europe
8.1 Europe Sales Volume and Revenue (2020-2031)
8.2 Europe Key Manufacturers Sales Revenue in 2024
8.3 Europe Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Type (2020-2031)
8.4 Europe Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Application (2020-2031)
8.5 Europe Growth Accelerators and Market Barriers
8.6 Europe Nutritional Supplements in Psychiatric Disorders Market Size by Country
8.6.1 Europe Revenue by Country
8.6.2 Europe Sales Trends by Country
8.6.3 Germany
8.6.4 France
8.6.5 U.K.
8.6.6 Italy
8.6.7 Russia
9 Asia-Pacific
9.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
9.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
9.3 Asia-Pacific Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Type (2020-2031)
9.4 Asia-Pacific Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Application (2020-2031)
9.5 Asia-Pacific Nutritional Supplements in Psychiatric Disorders Market Size by Region
9.5.1 Asia-Pacific Revenue by Region
9.5.2 Asia-Pacific Sales Trends by Region
9.6 Asia-Pacific Growth Accelerators and Market Barriers
9.7 Southeast Asia
9.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
9.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand
9.8 China
9.9 Japan
9.10 South Korea
9.11 China Taiwan
9.12 India
10 Central and South America
10.1 Central and South America Sales Volume and Revenue (2020-2031)
10.2 Central and South America Key Manufacturers Sales Revenue in 2024
10.3 Central and South America Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Type (2020-2031)
10.4 Central and South America Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Application (2020-2031)
10.5 Central and South America Investment Opportunities and Key Challenges
10.6 Central and South America Nutritional Supplements in Psychiatric Disorders Market Size by Country
10.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 Brazil
10.6.3 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
11.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
11.3 Middle East and Africa Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Type (2020-2031)
11.4 Middle East and Africa Nutritional Supplements in Psychiatric Disorders Sales and Revenue by Application (2020-2031)
11.5 Middle East and Africa Investment Opportunities and Key Challenges
11.6 Middle East and Africa Nutritional Supplements in Psychiatric Disorders Market Size by Country
11.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
11.6.2 GCC Countries
11.6.3 Turkey
11.6.4 Egypt
11.6.5 South Africa
12 Corporate Profile
12.1 Now Foods
12.1.1 Now Foods Corporation Information
12.1.2 Now Foods Business Overview
12.1.3 Now Foods Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.1.4 Now Foods Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.1.5 Now Foods Nutritional Supplements in Psychiatric Disorders Sales by Product in 2024
12.1.6 Now Foods Nutritional Supplements in Psychiatric Disorders Sales by Application in 2024
12.1.7 Now Foods Nutritional Supplements in Psychiatric Disorders Sales by Geographic Area in 2024
12.1.8 Now Foods Nutritional Supplements in Psychiatric Disorders SWOT Analysis
12.1.9 Now Foods Recent Developments
12.2 Nature’s Bounty
12.2.1 Nature’s Bounty Corporation Information
12.2.2 Nature’s Bounty Business Overview
12.2.3 Nature’s Bounty Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.2.4 Nature’s Bounty Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.2.5 Nature’s Bounty Nutritional Supplements in Psychiatric Disorders Sales by Product in 2024
12.2.6 Nature’s Bounty Nutritional Supplements in Psychiatric Disorders Sales by Application in 2024
12.2.7 Nature’s Bounty Nutritional Supplements in Psychiatric Disorders Sales by Geographic Area in 2024
12.2.8 Nature’s Bounty Nutritional Supplements in Psychiatric Disorders SWOT Analysis
12.2.9 Nature’s Bounty Recent Developments
12.3 Garden of Life
12.3.1 Garden of Life Corporation Information
12.3.2 Garden of Life Business Overview
12.3.3 Garden of Life Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.3.4 Garden of Life Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.3.5 Garden of Life Nutritional Supplements in Psychiatric Disorders Sales by Product in 2024
12.3.6 Garden of Life Nutritional Supplements in Psychiatric Disorders Sales by Application in 2024
12.3.7 Garden of Life Nutritional Supplements in Psychiatric Disorders Sales by Geographic Area in 2024
12.3.8 Garden of Life Nutritional Supplements in Psychiatric Disorders SWOT Analysis
12.3.9 Garden of Life Recent Developments
12.4 Nordic Naturals
12.4.1 Nordic Naturals Corporation Information
12.4.2 Nordic Naturals Business Overview
12.4.3 Nordic Naturals Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.4.4 Nordic Naturals Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.4.5 Nordic Naturals Nutritional Supplements in Psychiatric Disorders Sales by Product in 2024
12.4.6 Nordic Naturals Nutritional Supplements in Psychiatric Disorders Sales by Application in 2024
12.4.7 Nordic Naturals Nutritional Supplements in Psychiatric Disorders Sales by Geographic Area in 2024
12.4.8 Nordic Naturals Nutritional Supplements in Psychiatric Disorders SWOT Analysis
12.4.9 Nordic Naturals Recent Developments
12.5 Jarrow Formulas
12.5.1 Jarrow Formulas Corporation Information
12.5.2 Jarrow Formulas Business Overview
12.5.3 Jarrow Formulas Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.5.4 Jarrow Formulas Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.5.5 Jarrow Formulas Nutritional Supplements in Psychiatric Disorders Sales by Product in 2024
12.5.6 Jarrow Formulas Nutritional Supplements in Psychiatric Disorders Sales by Application in 2024
12.5.7 Jarrow Formulas Nutritional Supplements in Psychiatric Disorders Sales by Geographic Area in 2024
12.5.8 Jarrow Formulas Nutritional Supplements in Psychiatric Disorders SWOT Analysis
12.5.9 Jarrow Formulas Recent Developments
12.6 Thorne Research
12.6.1 Thorne Research Corporation Information
12.6.2 Thorne Research Business Overview
12.6.3 Thorne Research Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.6.4 Thorne Research Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.6.5 Thorne Research Recent Developments
12.7 Pure Encapsulations
12.7.1 Pure Encapsulations Corporation Information
12.7.2 Pure Encapsulations Business Overview
12.7.3 Pure Encapsulations Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.7.4 Pure Encapsulations Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.7.5 Pure Encapsulations Recent Developments
12.8 Integrative Therapeutics
12.8.1 Integrative Therapeutics Corporation Information
12.8.2 Integrative Therapeutics Business Overview
12.8.3 Integrative Therapeutics Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.8.4 Integrative Therapeutics Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.8.5 Integrative Therapeutics Recent Developments
12.9 Life Extension
12.9.1 Life Extension Corporation Information
12.9.2 Life Extension Business Overview
12.9.3 Life Extension Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.9.4 Life Extension Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.9.5 Life Extension Recent Developments
12.10 Metagenics
12.10.1 Metagenics Corporation Information
12.10.2 Metagenics Business Overview
12.10.3 Metagenics Nutritional Supplements in Psychiatric Disorders Product Models, Descriptions and Specifications
12.10.4 Metagenics Nutritional Supplements in Psychiatric Disorders Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.10.5 Metagenics Recent Developments
13 Value Chain and Supply-Chain Analysis
13.1 Nutritional Supplements in Psychiatric Disorders Industry Chain
13.2 Nutritional Supplements in Psychiatric Disorders Upstream Materials Analysis
13.2.1 Raw Materials
13.2.2 Key Suppliers Market Share & Risk Assessment
13.3 Nutritional Supplements in Psychiatric Disorders Integrated Production Analysis
13.3.1 Manufacturing Footprint Analysis
13.3.2 Production Technology Overview
13.3.3 Regional Cost Drivers
13.4 Nutritional Supplements in Psychiatric Disorders Sales Channels and Distribution Networks
13.4.1 Sales Channels
13.4.2 Distributors
14 Nutritional Supplements in Psychiatric Disorders Market Dynamics
14.1 Industry Trends and Evolution
14.2 Market Growth Drivers and Emerging Opportunities
14.3 Market Challenges, Risks, and Restraints
15 Key Findings in the Global Nutritional Supplements in Psychiatric Disorders Study
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.1.1 Research Programs/Design
16.1.1.2 Market Size Estimation
16.1.1.3 Market Breakdown and Data Triangulation
16.1.2 Data Source
16.1.2.1 Secondary Sources
16.1.2.2 Primary Sources
16.2 Author Details
List of Tables
Table 1. Global Nutritional Supplements in Psychiatric Disorders Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Nutritional Supplements in Psychiatric Disorders Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Nutritional Supplements in Psychiatric Disorders Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Nutritional Supplements in Psychiatric Disorders Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Nutritional Supplements in Psychiatric Disorders Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Nutritional Supplements in Psychiatric Disorders Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)
Table 7. Global Nutritional Supplements in Psychiatric Disorders Sales by Region (2020-2025) & (Tons)
Table 8. Global Nutritional Supplements in Psychiatric Disorders Sales by Region (2026-2031) & (Tons)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Nutritional Supplements in Psychiatric Disorders Production Growth Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)
Table 11. Global Nutritional Supplements in Psychiatric Disorders Production by Region (2020-2025) & (Tons)
Table 12. Global Nutritional Supplements in Psychiatric Disorders Production by Region (2026-2031) & (Tons)
Table 13. Global Nutritional Supplements in Psychiatric Disorders Sales by Manufacturers (2020-2025) & (Tons)
Table 14. Global Nutritional Supplements in Psychiatric Disorders Sales Share by Manufacturers (2020-2025)
Table 15. Global Nutritional Supplements in Psychiatric Disorders Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 16. Global Nutritional Supplements in Psychiatric Disorders Revenue Market Share by Manufacturers (2020-2025)
Table 17. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 18. Global Nutritional Supplements in Psychiatric Disorders by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nutritional Supplements in Psychiatric Disorders as of 2024)
Table 19. Global Nutritional Supplements in Psychiatric Disorders Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 20. Global Nutritional Supplements in Psychiatric Disorders Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Ton)
Table 21. Key Manufacturers Nutritional Supplements in Psychiatric Disorders Manufacturing Base and Headquarters
Table 22. Global Nutritional Supplements in Psychiatric Disorders Market Concentration Ratio (CR5 and HHI)
Table 23. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 24. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 25. Global Nutritional Supplements in Psychiatric Disorders Sales by Type (2020-2025) & (Tons)
Table 26. Global Nutritional Supplements in Psychiatric Disorders Sales by Type (2026-2031) & (Tons)
Table 27. Global Nutritional Supplements in Psychiatric Disorders Revenue by Type (2020-2025) & (US$ Million)
Table 28. Global Nutritional Supplements in Psychiatric Disorders Revenue by Type (2026-2031) & (US$ Million)
Table 29. Global Nutritional Supplements in Psychiatric Disorders ASP by Type (2020-2031) & (US$/Ton)
Table 30. Technical Specifications by Key Product Type
Table 31. Global Nutritional Supplements in Psychiatric Disorders Sales by Application (2020-2025) & (Tons)
Table 32. Global Nutritional Supplements in Psychiatric Disorders Sales by Application (2026-2031) & (Tons)
Table 33. Nutritional Supplements in Psychiatric Disorders High-Growth Sectors Demand CAGR (2024-2031)
Table 34. Global Nutritional Supplements in Psychiatric Disorders Revenue by Application (2020-2025) & (US$ Million)
Table 35. Global Nutritional Supplements in Psychiatric Disorders Revenue by Application (2026-2031) & (US$ Million)
Table 36. Global Nutritional Supplements in Psychiatric Disorders ASP by Application (2020-2031) & (US$/Ton)
Table 37. Top Customers by Region
Table 38. Top Customers by Application
Table 39. North America Nutritional Supplements in Psychiatric Disorders Growth Accelerators and Market Barriers
Table 40. North America Nutritional Supplements in Psychiatric Disorders Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 41. North America Nutritional Supplements in Psychiatric Disorders Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 42. Europe Nutritional Supplements in Psychiatric Disorders Growth Accelerators and Market Barriers
Table 43. Europe Nutritional Supplements in Psychiatric Disorders Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 44. Europe Nutritional Supplements in Psychiatric Disorders Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 45. Asia-Pacific Nutritional Supplements in Psychiatric Disorders Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Asia-Pacific Nutritional Supplements in Psychiatric Disorders Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 47. Asia-Pacific Nutritional Supplements in Psychiatric Disorders Growth Accelerators and Market Barriers
Table 48. Southeast Asia Nutritional Supplements in Psychiatric Disorders Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 49. Central and South America Nutritional Supplements in Psychiatric Disorders Investment Opportunities and Key Challenges
Table 50. Central and South America Nutritional Supplements in Psychiatric Disorders Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 51. Middle East and Africa Nutritional Supplements in Psychiatric Disorders Investment Opportunities and Key Challenges
Table 52. Middle East and Africa Nutritional Supplements in Psychiatric Disorders Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 53. Now Foods Corporation Information
Table 54. Now Foods Description and Major Businesses
Table 55. Now Foods Product Models, Descriptions and Specifications
Table 56. Now Foods Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 57. Now Foods Sales Value Proportion by Product in 2024
Table 58. Now Foods Sales Value Proportion by Application in 2024
Table 59. Now Foods Sales Value Proportion by Geographic Area in 2024
Table 60. Now Foods Nutritional Supplements in Psychiatric Disorders SWOT Analysis
Table 61. Now Foods Recent Developments
Table 62. Nature’s Bounty Corporation Information
Table 63. Nature’s Bounty Description and Major Businesses
Table 64. Nature’s Bounty Product Models, Descriptions and Specifications
Table 65. Nature’s Bounty Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 66. Nature’s Bounty Sales Value Proportion by Product in 2024
Table 67. Nature’s Bounty Sales Value Proportion by Application in 2024
Table 68. Nature’s Bounty Sales Value Proportion by Geographic Area in 2024
Table 69. Nature’s Bounty Nutritional Supplements in Psychiatric Disorders SWOT Analysis
Table 70. Nature’s Bounty Recent Developments
Table 71. Garden of Life Corporation Information
Table 72. Garden of Life Description and Major Businesses
Table 73. Garden of Life Product Models, Descriptions and Specifications
Table 74. Garden of Life Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 75. Garden of Life Sales Value Proportion by Product in 2024
Table 76. Garden of Life Sales Value Proportion by Application in 2024
Table 77. Garden of Life Sales Value Proportion by Geographic Area in 2024
Table 78. Garden of Life Nutritional Supplements in Psychiatric Disorders SWOT Analysis
Table 79. Garden of Life Recent Developments
Table 80. Nordic Naturals Corporation Information
Table 81. Nordic Naturals Description and Major Businesses
Table 82. Nordic Naturals Product Models, Descriptions and Specifications
Table 83. Nordic Naturals Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 84. Nordic Naturals Sales Value Proportion by Product in 2024
Table 85. Nordic Naturals Sales Value Proportion by Application in 2024
Table 86. Nordic Naturals Sales Value Proportion by Geographic Area in 2024
Table 87. Nordic Naturals Nutritional Supplements in Psychiatric Disorders SWOT Analysis
Table 88. Nordic Naturals Recent Developments
Table 89. Jarrow Formulas Corporation Information
Table 90. Jarrow Formulas Description and Major Businesses
Table 91. Jarrow Formulas Product Models, Descriptions and Specifications
Table 92. Jarrow Formulas Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 93. Jarrow Formulas Sales Value Proportion by Product in 2024
Table 94. Jarrow Formulas Sales Value Proportion by Application in 2024
Table 95. Jarrow Formulas Sales Value Proportion by Geographic Area in 2024
Table 96. Jarrow Formulas Nutritional Supplements in Psychiatric Disorders SWOT Analysis
Table 97. Jarrow Formulas Recent Developments
Table 98. Thorne Research Corporation Information
Table 99. Thorne Research Description and Major Businesses
Table 100. Thorne Research Product Models, Descriptions and Specifications
Table 101. Thorne Research Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 102. Thorne Research Recent Developments
Table 103. Pure Encapsulations Corporation Information
Table 104. Pure Encapsulations Description and Major Businesses
Table 105. Pure Encapsulations Product Models, Descriptions and Specifications
Table 106. Pure Encapsulations Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 107. Pure Encapsulations Recent Developments
Table 108. Integrative Therapeutics Corporation Information
Table 109. Integrative Therapeutics Description and Major Businesses
Table 110. Integrative Therapeutics Product Models, Descriptions and Specifications
Table 111. Integrative Therapeutics Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 112. Integrative Therapeutics Recent Developments
Table 113. Life Extension Corporation Information
Table 114. Life Extension Description and Major Businesses
Table 115. Life Extension Product Models, Descriptions and Specifications
Table 116. Life Extension Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 117. Life Extension Recent Developments
Table 118. Metagenics Corporation Information
Table 119. Metagenics Description and Major Businesses
Table 120. Metagenics Product Models, Descriptions and Specifications
Table 121. Metagenics Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 122. Metagenics Recent Developments
Table 123. Key Raw Materials Distribution
Table 124. Raw Materials Key Suppliers
Table 125. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 126. Milestones in Production Technology Evolution
Table 127. Distributors List
Table 128. Market Trends and Market Evolution
Table 129. Market Drivers and Opportunities
Table 130. Market Challenges, Risks, and Restraints
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Nutritional Supplements in Psychiatric Disorders Product Picture
Figure 2. Global Nutritional Supplements in Psychiatric Disorders Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Omega-3 Fatty Acids Product Picture
Figure 4. Amino Acids Product Picture
Figure 5. Vitamins Product Picture
Figure 6. Herbal Supplements Product Picture
Figure 7. Others Product Picture
Figure 8. Global Nutritional Supplements in Psychiatric Disorders Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Clinical Practice
Figure 10. Research and Development
Figure 11. Personalized Medicine
Figure 12. Other
Figure 13. Nutritional Supplements in Psychiatric Disorders Report Years Considered
Figure 14. Global Nutritional Supplements in Psychiatric Disorders Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 16. Global Nutritional Supplements in Psychiatric Disorders Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Nutritional Supplements in Psychiatric Disorders Revenue Market Share by Region (2020-2031)
Figure 18. Global Nutritional Supplements in Psychiatric Disorders Sales (2020-2031) & (Tons)
Figure 19. Global Nutritional Supplements in Psychiatric Disorders Sales (CAGR) by Region (2020-2031) (Tons)
Figure 20. Global Nutritional Supplements in Psychiatric Disorders Sales Market Share by Region (2020-2031)
Figure 21. Global Nutritional Supplements in Psychiatric Disorders Capacity, Production and Utilization (2020-2031) & (Tons)
Figure 22. Global Nutritional Supplements in Psychiatric Disorders Production Trend by Region (2020-2031) (Tons)
Figure 23. Global Nutritional Supplements in Psychiatric Disorders Production Market Share by Region (2020-2031)
Figure 24. Production Capacity Enablers & Constraints
Figure 25. Nutritional Supplements in Psychiatric Disorders Production Growth Rate in North America (2020-2031) & (Tons)
Figure 26. Nutritional Supplements in Psychiatric Disorders Production Growth Rate in Europe (2020-2031) & (Tons)
Figure 27. Nutritional Supplements in Psychiatric Disorders Production Growth Rate in China (2020-2031) & (Tons)
Figure 28. Nutritional Supplements in Psychiatric Disorders Production Growth Rate in Japan (2020-2031) & (Tons)
Figure 29. Top 5 and Top 10 Manufacturers Nutritional Supplements in Psychiatric Disorders Sales Volume Market Share in 2024
Figure 30. Global Nutritional Supplements in Psychiatric Disorders Revenue Market Share Ranking (2024)
Figure 31. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 32. Omega-3 Fatty Acids Revenue Market Share by Manufacturer in 2024
Figure 33. Amino Acids Revenue Market Share by Manufacturer in 2024
Figure 34. Vitamins Revenue Market Share by Manufacturer in 2024
Figure 35. Herbal Supplements Revenue Market Share by Manufacturer in 2024
Figure 36. Others Revenue Market Share by Manufacturer in 2024
Figure 37. Type Eight Revenue Market Share by Manufacturer in 2024
Figure 38. Type Nine Revenue Market Share by Manufacturer in 2024
Figure 39. Global Nutritional Supplements in Psychiatric Disorders Sales Market Share by Type (2020-2031)
Figure 40. Global Nutritional Supplements in Psychiatric Disorders Revenue Market Share by Type (2020-2031)
Figure 41. Global Nutritional Supplements in Psychiatric Disorders Sales Market Share by Application (2020-2031)
Figure 42. Global Nutritional Supplements in Psychiatric Disorders Revenue Market Share by Application (2020-2031)
Figure 43. North America Nutritional Supplements in Psychiatric Disorders Sales YoY (2020-2031) & (Tons)
Figure 44. North America Nutritional Supplements in Psychiatric Disorders Revenue YoY (2020-2031) & (US$ Million)
Figure 45. North America Top 5 Manufacturers Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) in 2024
Figure 46. North America Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Type (2020- 2031)
Figure 47. North America Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 48. North America Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Application (2020-2031)
Figure 49. North America Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Application (2020-2031)
Figure 50. US Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 51. Canada Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 52. Mexico Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 53. Europe Nutritional Supplements in Psychiatric Disorders Sales YoY (2020-2031) & (Tons)
Figure 54. Europe Nutritional Supplements in Psychiatric Disorders Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Europe Top 5 Manufacturers Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) in 2024
Figure 56. Europe Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Type (2020-2031)
Figure 57. Europe Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Type (2020-2031)
Figure 58. Europe Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Application (2020-2031)
Figure 59. Europe Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Application (2020-2031)
Figure 60. Germany Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 61. France Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 62. U.K. Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 63. Italy Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 64. Russia Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 65. Asia-Pacific Nutritional Supplements in Psychiatric Disorders Sales YoY (2020-2031) & (Tons)
Figure 66. Asia-Pacific Nutritional Supplements in Psychiatric Disorders Revenue YoY (2020-2031) & (US$ Million)
Figure 67. Asia-Pacific Top 8 Manufacturers Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) in 2024
Figure 68. Asia-Pacific Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Type (2020- 2031)
Figure 69. Asia-Pacific Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 70. Asia-Pacific Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Application (2020-2031)
Figure 71. Asia-Pacific Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Application (2020-2031)
Figure 72. Indonesia Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 73. Japan Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 74. South Korea Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 75. China Taiwan Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 76. India Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 77. Central and South America Nutritional Supplements in Psychiatric Disorders Sales YoY (2020-2031) & (Tons)
Figure 78. Central and South America Nutritional Supplements in Psychiatric Disorders Revenue YoY (2020-2031) & (US$ Million)
Figure 79. Central and South America Top 5 Manufacturers Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) in 2024
Figure 80. Central and South America Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Type (2021-2031)
Figure 81. Central and South America Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Type (2020-2031)
Figure 82. Central and South America Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Application (2020-2031)
Figure 83. Central and South America Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Application (2020-2031)
Figure 84. Brazil Nutritional Supplements in Psychiatric Disorders Revenue (2020-2025) & (US$ Million)
Figure 85. Argentina Nutritional Supplements in Psychiatric Disorders Revenue (2020-2025) & (US$ Million)
Figure 86. Middle East, and Africa Nutritional Supplements in Psychiatric Disorders Sales YoY (2020-2031) & (Tons)
Figure 87. Middle East and Africa Nutritional Supplements in Psychiatric Disorders Revenue YoY (2020-2031) & (US$ Million)
Figure 88. Middle East and Africa Top 5 Manufacturers Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) in 2024
Figure 89. Middle East and Africa Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Type (2021-2031)
Figure 90. South America Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Type (2020-2031)
Figure 91. Middle East and Africa Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Application (2020-2031)
Figure 92. Middle East and Africa Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Application (2020-2031)
Figure 93. GCC Countries Nutritional Supplements in Psychiatric Disorders Revenue (2020-2025) & (US$ Million)
Figure 94. Turkey Nutritional Supplements in Psychiatric Disorders Revenue (2020-2025) & (US$ Million)
Figure 95. Egypt Nutritional Supplements in Psychiatric Disorders Revenue (2020-2025) & (US$ Million)
Figure 96. South Africa Nutritional Supplements in Psychiatric Disorders Revenue (2020-2025) & (US$ Million)
Figure 97. Nutritional Supplements in Psychiatric Disorders Industry Chain Mapping
Figure 98. Regional Nutritional Supplements in Psychiatric Disorders Manufacturing Base Distribution (%)
Figure 99. Nutritional Supplements in Psychiatric Disorders Production Process
Figure 100. Regional Nutritional Supplements in Psychiatric Disorders Production Cost Structure
Figure 101. Channels of Distribution (Direct Vs Distribution)
Figure 102. Bottom-up and Top-down Approaches for This Report
Figure 103. Data Triangulation
Figure 104. Key Executives Interviewed
Table 1. Global Nutritional Supplements in Psychiatric Disorders Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Nutritional Supplements in Psychiatric Disorders Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Nutritional Supplements in Psychiatric Disorders Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Nutritional Supplements in Psychiatric Disorders Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Nutritional Supplements in Psychiatric Disorders Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Nutritional Supplements in Psychiatric Disorders Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)
Table 7. Global Nutritional Supplements in Psychiatric Disorders Sales by Region (2020-2025) & (Tons)
Table 8. Global Nutritional Supplements in Psychiatric Disorders Sales by Region (2026-2031) & (Tons)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Nutritional Supplements in Psychiatric Disorders Production Growth Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)
Table 11. Global Nutritional Supplements in Psychiatric Disorders Production by Region (2020-2025) & (Tons)
Table 12. Global Nutritional Supplements in Psychiatric Disorders Production by Region (2026-2031) & (Tons)
Table 13. Global Nutritional Supplements in Psychiatric Disorders Sales by Manufacturers (2020-2025) & (Tons)
Table 14. Global Nutritional Supplements in Psychiatric Disorders Sales Share by Manufacturers (2020-2025)
Table 15. Global Nutritional Supplements in Psychiatric Disorders Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 16. Global Nutritional Supplements in Psychiatric Disorders Revenue Market Share by Manufacturers (2020-2025)
Table 17. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 18. Global Nutritional Supplements in Psychiatric Disorders by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nutritional Supplements in Psychiatric Disorders as of 2024)
Table 19. Global Nutritional Supplements in Psychiatric Disorders Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 20. Global Nutritional Supplements in Psychiatric Disorders Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Ton)
Table 21. Key Manufacturers Nutritional Supplements in Psychiatric Disorders Manufacturing Base and Headquarters
Table 22. Global Nutritional Supplements in Psychiatric Disorders Market Concentration Ratio (CR5 and HHI)
Table 23. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 24. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 25. Global Nutritional Supplements in Psychiatric Disorders Sales by Type (2020-2025) & (Tons)
Table 26. Global Nutritional Supplements in Psychiatric Disorders Sales by Type (2026-2031) & (Tons)
Table 27. Global Nutritional Supplements in Psychiatric Disorders Revenue by Type (2020-2025) & (US$ Million)
Table 28. Global Nutritional Supplements in Psychiatric Disorders Revenue by Type (2026-2031) & (US$ Million)
Table 29. Global Nutritional Supplements in Psychiatric Disorders ASP by Type (2020-2031) & (US$/Ton)
Table 30. Technical Specifications by Key Product Type
Table 31. Global Nutritional Supplements in Psychiatric Disorders Sales by Application (2020-2025) & (Tons)
Table 32. Global Nutritional Supplements in Psychiatric Disorders Sales by Application (2026-2031) & (Tons)
Table 33. Nutritional Supplements in Psychiatric Disorders High-Growth Sectors Demand CAGR (2024-2031)
Table 34. Global Nutritional Supplements in Psychiatric Disorders Revenue by Application (2020-2025) & (US$ Million)
Table 35. Global Nutritional Supplements in Psychiatric Disorders Revenue by Application (2026-2031) & (US$ Million)
Table 36. Global Nutritional Supplements in Psychiatric Disorders ASP by Application (2020-2031) & (US$/Ton)
Table 37. Top Customers by Region
Table 38. Top Customers by Application
Table 39. North America Nutritional Supplements in Psychiatric Disorders Growth Accelerators and Market Barriers
Table 40. North America Nutritional Supplements in Psychiatric Disorders Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 41. North America Nutritional Supplements in Psychiatric Disorders Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 42. Europe Nutritional Supplements in Psychiatric Disorders Growth Accelerators and Market Barriers
Table 43. Europe Nutritional Supplements in Psychiatric Disorders Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 44. Europe Nutritional Supplements in Psychiatric Disorders Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 45. Asia-Pacific Nutritional Supplements in Psychiatric Disorders Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Asia-Pacific Nutritional Supplements in Psychiatric Disorders Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 47. Asia-Pacific Nutritional Supplements in Psychiatric Disorders Growth Accelerators and Market Barriers
Table 48. Southeast Asia Nutritional Supplements in Psychiatric Disorders Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 49. Central and South America Nutritional Supplements in Psychiatric Disorders Investment Opportunities and Key Challenges
Table 50. Central and South America Nutritional Supplements in Psychiatric Disorders Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 51. Middle East and Africa Nutritional Supplements in Psychiatric Disorders Investment Opportunities and Key Challenges
Table 52. Middle East and Africa Nutritional Supplements in Psychiatric Disorders Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 53. Now Foods Corporation Information
Table 54. Now Foods Description and Major Businesses
Table 55. Now Foods Product Models, Descriptions and Specifications
Table 56. Now Foods Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 57. Now Foods Sales Value Proportion by Product in 2024
Table 58. Now Foods Sales Value Proportion by Application in 2024
Table 59. Now Foods Sales Value Proportion by Geographic Area in 2024
Table 60. Now Foods Nutritional Supplements in Psychiatric Disorders SWOT Analysis
Table 61. Now Foods Recent Developments
Table 62. Nature’s Bounty Corporation Information
Table 63. Nature’s Bounty Description and Major Businesses
Table 64. Nature’s Bounty Product Models, Descriptions and Specifications
Table 65. Nature’s Bounty Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 66. Nature’s Bounty Sales Value Proportion by Product in 2024
Table 67. Nature’s Bounty Sales Value Proportion by Application in 2024
Table 68. Nature’s Bounty Sales Value Proportion by Geographic Area in 2024
Table 69. Nature’s Bounty Nutritional Supplements in Psychiatric Disorders SWOT Analysis
Table 70. Nature’s Bounty Recent Developments
Table 71. Garden of Life Corporation Information
Table 72. Garden of Life Description and Major Businesses
Table 73. Garden of Life Product Models, Descriptions and Specifications
Table 74. Garden of Life Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 75. Garden of Life Sales Value Proportion by Product in 2024
Table 76. Garden of Life Sales Value Proportion by Application in 2024
Table 77. Garden of Life Sales Value Proportion by Geographic Area in 2024
Table 78. Garden of Life Nutritional Supplements in Psychiatric Disorders SWOT Analysis
Table 79. Garden of Life Recent Developments
Table 80. Nordic Naturals Corporation Information
Table 81. Nordic Naturals Description and Major Businesses
Table 82. Nordic Naturals Product Models, Descriptions and Specifications
Table 83. Nordic Naturals Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 84. Nordic Naturals Sales Value Proportion by Product in 2024
Table 85. Nordic Naturals Sales Value Proportion by Application in 2024
Table 86. Nordic Naturals Sales Value Proportion by Geographic Area in 2024
Table 87. Nordic Naturals Nutritional Supplements in Psychiatric Disorders SWOT Analysis
Table 88. Nordic Naturals Recent Developments
Table 89. Jarrow Formulas Corporation Information
Table 90. Jarrow Formulas Description and Major Businesses
Table 91. Jarrow Formulas Product Models, Descriptions and Specifications
Table 92. Jarrow Formulas Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 93. Jarrow Formulas Sales Value Proportion by Product in 2024
Table 94. Jarrow Formulas Sales Value Proportion by Application in 2024
Table 95. Jarrow Formulas Sales Value Proportion by Geographic Area in 2024
Table 96. Jarrow Formulas Nutritional Supplements in Psychiatric Disorders SWOT Analysis
Table 97. Jarrow Formulas Recent Developments
Table 98. Thorne Research Corporation Information
Table 99. Thorne Research Description and Major Businesses
Table 100. Thorne Research Product Models, Descriptions and Specifications
Table 101. Thorne Research Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 102. Thorne Research Recent Developments
Table 103. Pure Encapsulations Corporation Information
Table 104. Pure Encapsulations Description and Major Businesses
Table 105. Pure Encapsulations Product Models, Descriptions and Specifications
Table 106. Pure Encapsulations Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 107. Pure Encapsulations Recent Developments
Table 108. Integrative Therapeutics Corporation Information
Table 109. Integrative Therapeutics Description and Major Businesses
Table 110. Integrative Therapeutics Product Models, Descriptions and Specifications
Table 111. Integrative Therapeutics Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 112. Integrative Therapeutics Recent Developments
Table 113. Life Extension Corporation Information
Table 114. Life Extension Description and Major Businesses
Table 115. Life Extension Product Models, Descriptions and Specifications
Table 116. Life Extension Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 117. Life Extension Recent Developments
Table 118. Metagenics Corporation Information
Table 119. Metagenics Description and Major Businesses
Table 120. Metagenics Product Models, Descriptions and Specifications
Table 121. Metagenics Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 122. Metagenics Recent Developments
Table 123. Key Raw Materials Distribution
Table 124. Raw Materials Key Suppliers
Table 125. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 126. Milestones in Production Technology Evolution
Table 127. Distributors List
Table 128. Market Trends and Market Evolution
Table 129. Market Drivers and Opportunities
Table 130. Market Challenges, Risks, and Restraints
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Nutritional Supplements in Psychiatric Disorders Product Picture
Figure 2. Global Nutritional Supplements in Psychiatric Disorders Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Omega-3 Fatty Acids Product Picture
Figure 4. Amino Acids Product Picture
Figure 5. Vitamins Product Picture
Figure 6. Herbal Supplements Product Picture
Figure 7. Others Product Picture
Figure 8. Global Nutritional Supplements in Psychiatric Disorders Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Clinical Practice
Figure 10. Research and Development
Figure 11. Personalized Medicine
Figure 12. Other
Figure 13. Nutritional Supplements in Psychiatric Disorders Report Years Considered
Figure 14. Global Nutritional Supplements in Psychiatric Disorders Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 16. Global Nutritional Supplements in Psychiatric Disorders Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Nutritional Supplements in Psychiatric Disorders Revenue Market Share by Region (2020-2031)
Figure 18. Global Nutritional Supplements in Psychiatric Disorders Sales (2020-2031) & (Tons)
Figure 19. Global Nutritional Supplements in Psychiatric Disorders Sales (CAGR) by Region (2020-2031) (Tons)
Figure 20. Global Nutritional Supplements in Psychiatric Disorders Sales Market Share by Region (2020-2031)
Figure 21. Global Nutritional Supplements in Psychiatric Disorders Capacity, Production and Utilization (2020-2031) & (Tons)
Figure 22. Global Nutritional Supplements in Psychiatric Disorders Production Trend by Region (2020-2031) (Tons)
Figure 23. Global Nutritional Supplements in Psychiatric Disorders Production Market Share by Region (2020-2031)
Figure 24. Production Capacity Enablers & Constraints
Figure 25. Nutritional Supplements in Psychiatric Disorders Production Growth Rate in North America (2020-2031) & (Tons)
Figure 26. Nutritional Supplements in Psychiatric Disorders Production Growth Rate in Europe (2020-2031) & (Tons)
Figure 27. Nutritional Supplements in Psychiatric Disorders Production Growth Rate in China (2020-2031) & (Tons)
Figure 28. Nutritional Supplements in Psychiatric Disorders Production Growth Rate in Japan (2020-2031) & (Tons)
Figure 29. Top 5 and Top 10 Manufacturers Nutritional Supplements in Psychiatric Disorders Sales Volume Market Share in 2024
Figure 30. Global Nutritional Supplements in Psychiatric Disorders Revenue Market Share Ranking (2024)
Figure 31. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 32. Omega-3 Fatty Acids Revenue Market Share by Manufacturer in 2024
Figure 33. Amino Acids Revenue Market Share by Manufacturer in 2024
Figure 34. Vitamins Revenue Market Share by Manufacturer in 2024
Figure 35. Herbal Supplements Revenue Market Share by Manufacturer in 2024
Figure 36. Others Revenue Market Share by Manufacturer in 2024
Figure 37. Type Eight Revenue Market Share by Manufacturer in 2024
Figure 38. Type Nine Revenue Market Share by Manufacturer in 2024
Figure 39. Global Nutritional Supplements in Psychiatric Disorders Sales Market Share by Type (2020-2031)
Figure 40. Global Nutritional Supplements in Psychiatric Disorders Revenue Market Share by Type (2020-2031)
Figure 41. Global Nutritional Supplements in Psychiatric Disorders Sales Market Share by Application (2020-2031)
Figure 42. Global Nutritional Supplements in Psychiatric Disorders Revenue Market Share by Application (2020-2031)
Figure 43. North America Nutritional Supplements in Psychiatric Disorders Sales YoY (2020-2031) & (Tons)
Figure 44. North America Nutritional Supplements in Psychiatric Disorders Revenue YoY (2020-2031) & (US$ Million)
Figure 45. North America Top 5 Manufacturers Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) in 2024
Figure 46. North America Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Type (2020- 2031)
Figure 47. North America Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 48. North America Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Application (2020-2031)
Figure 49. North America Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Application (2020-2031)
Figure 50. US Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 51. Canada Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 52. Mexico Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 53. Europe Nutritional Supplements in Psychiatric Disorders Sales YoY (2020-2031) & (Tons)
Figure 54. Europe Nutritional Supplements in Psychiatric Disorders Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Europe Top 5 Manufacturers Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) in 2024
Figure 56. Europe Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Type (2020-2031)
Figure 57. Europe Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Type (2020-2031)
Figure 58. Europe Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Application (2020-2031)
Figure 59. Europe Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Application (2020-2031)
Figure 60. Germany Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 61. France Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 62. U.K. Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 63. Italy Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 64. Russia Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 65. Asia-Pacific Nutritional Supplements in Psychiatric Disorders Sales YoY (2020-2031) & (Tons)
Figure 66. Asia-Pacific Nutritional Supplements in Psychiatric Disorders Revenue YoY (2020-2031) & (US$ Million)
Figure 67. Asia-Pacific Top 8 Manufacturers Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) in 2024
Figure 68. Asia-Pacific Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Type (2020- 2031)
Figure 69. Asia-Pacific Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 70. Asia-Pacific Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Application (2020-2031)
Figure 71. Asia-Pacific Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Application (2020-2031)
Figure 72. Indonesia Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 73. Japan Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 74. South Korea Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 75. China Taiwan Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 76. India Nutritional Supplements in Psychiatric Disorders Revenue (2020-2031) & (US$ Million)
Figure 77. Central and South America Nutritional Supplements in Psychiatric Disorders Sales YoY (2020-2031) & (Tons)
Figure 78. Central and South America Nutritional Supplements in Psychiatric Disorders Revenue YoY (2020-2031) & (US$ Million)
Figure 79. Central and South America Top 5 Manufacturers Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) in 2024
Figure 80. Central and South America Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Type (2021-2031)
Figure 81. Central and South America Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Type (2020-2031)
Figure 82. Central and South America Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Application (2020-2031)
Figure 83. Central and South America Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Application (2020-2031)
Figure 84. Brazil Nutritional Supplements in Psychiatric Disorders Revenue (2020-2025) & (US$ Million)
Figure 85. Argentina Nutritional Supplements in Psychiatric Disorders Revenue (2020-2025) & (US$ Million)
Figure 86. Middle East, and Africa Nutritional Supplements in Psychiatric Disorders Sales YoY (2020-2031) & (Tons)
Figure 87. Middle East and Africa Nutritional Supplements in Psychiatric Disorders Revenue YoY (2020-2031) & (US$ Million)
Figure 88. Middle East and Africa Top 5 Manufacturers Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) in 2024
Figure 89. Middle East and Africa Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Type (2021-2031)
Figure 90. South America Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Type (2020-2031)
Figure 91. Middle East and Africa Nutritional Supplements in Psychiatric Disorders Sales Volume (Tons) by Application (2020-2031)
Figure 92. Middle East and Africa Nutritional Supplements in Psychiatric Disorders Sales Revenue (US$ Million) by Application (2020-2031)
Figure 93. GCC Countries Nutritional Supplements in Psychiatric Disorders Revenue (2020-2025) & (US$ Million)
Figure 94. Turkey Nutritional Supplements in Psychiatric Disorders Revenue (2020-2025) & (US$ Million)
Figure 95. Egypt Nutritional Supplements in Psychiatric Disorders Revenue (2020-2025) & (US$ Million)
Figure 96. South Africa Nutritional Supplements in Psychiatric Disorders Revenue (2020-2025) & (US$ Million)
Figure 97. Nutritional Supplements in Psychiatric Disorders Industry Chain Mapping
Figure 98. Regional Nutritional Supplements in Psychiatric Disorders Manufacturing Base Distribution (%)
Figure 99. Nutritional Supplements in Psychiatric Disorders Production Process
Figure 100. Regional Nutritional Supplements in Psychiatric Disorders Production Cost Structure
Figure 101. Channels of Distribution (Direct Vs Distribution)
Figure 102. Bottom-up and Top-down Approaches for This Report
Figure 103. Data Triangulation
Figure 104. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Wireless Split Keyboard Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Global Ergonomic Adjustable Computer Chair Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Global Trackless Keyboard Tray Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232